Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neurology

Biology & Differential Diagnosis: What MG Is and Isn't

At a Glance

Myasthenia Gravis (MG) is an autoimmune disorder that disrupts communication between nerves and muscles, causing weakness that worsens with use. Unlike MS or ALS, MG does not damage the brain or spinal cord, and it requires specific tests to distinguish it from strokes and other rare conditions.

Understanding Myasthenia Gravis (MG) often begins with clearing up what it is not. Because MG is rare and its symptoms—like slurred speech or droopy eyes—can appear suddenly, it is frequently mistaken for more common or well-known conditions [1][2].

What MG Is: A Communication Error

At its core, MG is a disorder of the neuromuscular junction (NMJ), the place where your nerves “talk” to your muscles [3][4]. In a healthy body, a nerve sends a chemical signal called acetylcholine across a small gap. This signal lands on a receptor (a “docking station”) on the muscle, telling it to contract [5][6].

In MG, your immune system produces autoantibodies that disrupt this conversation in different ways depending on which protein they target:

  • Anti-AChR (Acetylcholine Receptor): These antibodies are like “wrecking balls.” they activate the complement system (a part of the immune system), which physically destroys or simplifies the docking stations [5][7].
  • Anti-MuSK (Muscle-Specific Kinase): These act more like “jammers.” They don’t destroy the receptors but instead block the signaling path that keeps the docking stations organized and healthy [8][5].
  • Anti-LRP4: These also interfere with the signaling cluster, preventing the muscle from maintaining its “readiness” to receive signals [9][6].

What MG Is Not: Clearing the Confusion

It is common for patients to fear they have a degenerative disease of the brain or spinal cord. However, MG is a peripheral disease, meaning it only affects the connection to the muscles, not the “hard drive” (the brain) or “cables” (the spinal cord) [10][11].

Condition Primary Location Key Difference from MG
Multiple Sclerosis (MS) Central Nervous System (Brain/Spine) MS involves damage to the protective coating of nerves (myelin). It does not typically cause the “fatigability” (worsening with use) seen in MG [12][13].
ALS (Lou Gehrig’s) Motor Neurons ALS causes permanent muscle wasting and twitching (fasciculations). MG weakness is fluctuating and usually does not cause muscle death [14][15].
Stroke / TIA Brain (Vascular) Bulbar symptoms (slurred speech, swallowing issues) can look like a stroke, but a stroke is a sudden “event” on one side of the body, whereas MG symptoms often fluctuate and affect both sides over time [1][2].

The “Look-Alikes”

Doctors use specific tools to distinguish MG from other rare neuromuscular conditions:

  • Lambert-Eaton Myasthenic Syndrome (LEMS): Unlike MG, which gets worse with use, LEMS often improves briefly after a few seconds of exercise [16][17]. LEMS also causes “autonomic” symptoms like dry mouth, which are not found in MG [16][18].
  • Botulism: While both cause weakness, botulism usually presents with a “descending” pattern (starting at the head and moving down rapidly) and severe autonomic dysfunction [12][18].
  • Congenital Myasthenic Syndromes (CMS): These are genetic conditions present from birth, not caused by an autoimmune attack, and they do not respond to immunosuppressant treatments [12].

By identifying exactly where the communication is breaking down, your medical team can ensure you receive the correct treatment for your specific type of MG. For details on how doctors classify your disease, read about Subtypes & Classification.

Common questions in this guide

How is Myasthenia Gravis different from Multiple Sclerosis or ALS?
Myasthenia Gravis is a peripheral disease affecting the connection between nerves and muscles, causing weakness that fluctuates. MS damages nerve coatings in the brain and spine, while ALS causes permanent muscle wasting and twitching, neither of which are typical in MG.
Why do doctors test for different antibodies like AChR or MuSK?
Different antibodies disrupt nerve-muscle communication in unique ways. For example, anti-AChR antibodies physically destroy the muscle's receptor stations, while anti-MuSK antibodies act like jammers that block the signals needed to keep these stations healthy.
Could my sudden slurred speech be a stroke instead of Myasthenia Gravis?
While sudden slurred speech or swallowing issues can look like a stroke, a stroke is usually a sudden event affecting one side of the body. Myasthenia Gravis symptoms often fluctuate throughout the day and can affect both sides of the body over time.
How do doctors tell the difference between Myasthenia Gravis and Lambert-Eaton syndrome?
Weakness from Myasthenia Gravis typically worsens the more you use your muscles. In contrast, Lambert-Eaton syndrome often improves briefly after a few seconds of exercise and frequently includes symptoms like dry mouth, which are not found in MG.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my antibody status (e.g., AChR vs. MuSK), is my condition caused by the destruction of receptors or a signaling disruption?
  2. 2.Why did you choose a specific test (like SFEMG or RNS) to confirm my diagnosis over others?
  3. 3.How did you rule out other conditions that look like MG, such as LEMS or a small stroke?
  4. 4.If my symptoms primarily affect my speech and swallowing, what are the 'red flags' that would indicate a crisis rather than just a flare-up?
  5. 5.Does my MG affect my reflexes or autonomic system (like heart rate or digestion), or is it strictly limited to voluntary muscles?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Unilateral Ptosis and Bulbar Symptoms as the Initial Presentation of Late-Onset Acetylcholine Receptor Antibody-Positive Myasthenia Gravis Mimicking Acute Ischemic Stroke in an 82-Year-Old Man.

    Mangrio SM, Faisal S, Malik Z, et al.

    Cureus 2025; (17(12)):e99832 doi:10.7759/cureus.99832.

    PMID: 41573440
  2. 2

    Analysis of events from sudden isolated dysarthria to diagnosis of myasthenic crisis: myasthenia gravis mimicking acute lacunar stroke-a case report.

    Miletic SP, Ahmed SRB

    Journal of medical case reports 2024; (18(1)):319 doi:10.1186/s13256-024-04617-w.

    PMID: 38961428
  3. 3

    Myasthenia Gravis: A Rare Neurologic Complication of Immune Checkpoint Inhibitor Therapy.

    Shames Y, Errante M, Keteku NP

    Journal of the advanced practitioner in oncology 2022; (13(2)):151-157 doi:10.6004/jadpro.2022.13.2.6.

    PMID: 35369395
  4. 4

    Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: New Developments in Diagnosis and Treatment.

    Pascuzzi RM, Bodkin CL

    Neuropsychiatric disease and treatment 2022; (18()):3001-3022 doi:10.2147/NDT.S296714.

    PMID: 36578903
  5. 5

    Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.

    Phillips WD, Vincent A

    F1000Research 2016; (5()).

    PMID: 27408701
  6. 6

    Autoantibodies in myasthenia gravis.

    Fichtner ML, Horstkorte L, Sánchez Navarro BG, et al.

    International review of neurobiology 2025; (182()):89-119 doi:10.1016/bs.irn.2025.04.024.

    PMID: 40675742
  7. 7

    Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations.

    Dresser L, Wlodarski R, Rezania K, Soliven B

    Journal of clinical medicine 2021; (10(11)) doi:10.3390/jcm10112235.

    PMID: 34064035
  8. 8

    Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment.

    Cao M, Koneczny I, Vincent A

    Frontiers in molecular neuroscience 2020; (13()):159 doi:10.3389/fnmol.2020.00159.

    PMID: 32982689
  9. 9

    Sorting nexin 17 increases low-density lipoprotein receptor-related protein 4 membrane expression: A novel mechanism of acetylcholine receptor aggregation in myasthenia gravis.

    He X, Zhou S, Ji Y, et al.

    Frontiers in immunology 2022; (13()):916098 doi:10.3389/fimmu.2022.916098.

    PMID: 36311763
  10. 10

    MuSK cysteine-rich domain antibodies are pathogenic in a mouse model of autoimmune myasthenia gravis.

    Halliez M, Cottin S, You A, et al.

    The Journal of clinical investigation 2025; (135(15)).

    PMID: 40504622
  11. 11

    Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.

    Hurst RL, Gooch CL

    Current neurology and neuroscience reports 2016; (16(7)):61 doi:10.1007/s11910-016-0668-z.

    PMID: 27170368
  12. 12

    Botulism, Lambert-Eaton Myasthenic Syndrome, and Congenital Myasthenic Syndromes.

    Ramdas S

    Continuum (Minneapolis, Minn.) 2025; (31(5)):1303-1328 doi:10.1212/cont.0000000000001613.

    PMID: 41037175
  13. 13

    Atypical presentation of Lambert-Eaton myasthenic syndrome associated with oesophageal squamous cell carcinoma.

    Bubuioc AM, Gagiu A, Cojocaru L, Lisnic V

    BMJ case reports 2025; (18(3)) doi:10.1136/bcr-2024-264472.

    PMID: 40044483
  14. 14

    Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.

    Bodkin C, Pascuzzi RM

    Neurologic clinics 2021; (39(1)):133-146 doi:10.1016/j.ncl.2020.09.007.

    PMID: 33223079
  15. 15

    Neuromuscular junction disorders.

    Verschuuren J, Strijbos E, Vincent A

    Handbook of clinical neurology 2016; (133()):447-66.

    PMID: 27112691
  16. 16

    Ophthalmoplegia associated with lung adenocarcinoma in a patient with the Lambert-Eaton myasthenic syndrome: A case report.

    Tang Y, Wang K, Chen Z, et al.

    Medicine 2017; (96(22)):e6484 doi:10.1097/MD.0000000000006484.

    PMID: 28562525
  17. 17

    Acute onset of Lambert Eaton myasthenic syndrome in prostate adenocarcinoma: a case report.

    Drăghici NC, Olariu E, Lupescu TD, Mureşanu FD

    Medicine and pharmacy reports 2024; (97(1)):95-98 doi:10.15386/mpr-2541.

    PMID: 38344339
  18. 18

    Presynaptic Disorders: Lambert-Eaton Myasthenic Syndrome and Botulism.

    Gable KL, Massey JM

    Seminars in neurology 2015; (35(4)):340-6 doi:10.1055/s-0035-1558976.

    PMID: 26502758

This page explains the biology and differential diagnosis of Myasthenia Gravis for educational purposes. Always consult a neurologist for an accurate diagnosis and medical advice regarding your specific symptoms.

Get notified when new evidence is published on Myasthenia gravis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.